Testosterone deficiency

Chemicals with antiandrogenic activity inclnde pharmacenticals developed as anticancer agents (e.g., flntamide, Neri and Monahan 1972 Neri et al. 1972, in Lntsky et al. 1975) and 179-methyltestosterone nsed to treat testosterone deficiency (Katsiadaki et al. 2006). Other antiandrogens inclnde varions pesticides snch as the... 

Replacement therapy - Replacement therapy in hypogonadism associated with a deficiency or absence of endogenous testosterone. Prior to puberty, androgen replacement therapy is needed for development of secondary sexual characteristics. Prolonged treatment is required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are of primary importance. 

Testosterone Gel For replacement therapy in male with testosterone deficiencies and hypogonadotropic hypoganadism... 

Testosterone Spray For replacement therapy in males with testosterone deficiency... 

Finally, sex steroids are also implicated in the pathophysiology of depression. Estrogen deficiency states, which occur in the postpartum and postmenopausal periods, are thought to play a role in the etiology of depression in some women. Likewise, severe testosterone deficiency in men is sometimes associated with depressive symptoms. Hormone replacement therapy in hypogonadal men and women may be associated with an improvement in mood and depressive symptoms. 

Dobs AS, Matsumoto AM, Wang C, Kipnes MS. Shortterm pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 2004 20 729-38. 

Davis S. Testosterone deficiency in women. J Reprod Med 2001 46(Suppl 3) 291-6. 

As previously mentioned, degradable microspheres have gained attention as promising delivery vehicles for steroids in postmenopausal therapy. Copolymers of CL and d,l-LA were used to prepare microspheres for prolonged release of progesterone and [5-estradiol. The system offered a constant release for up to 40 days in vitro and 70 days in vivo [226]. Similarly, PCL copolymers have been considered useful for androgen replacement therapy in the treatment of aging men with a testosterone deficiency. Micelles of PCL-block-poly(ethylene oxide) released dihydrotestosterone in a controlled fashion over 30 days. The biocompatibility was confirmed in vitro in a HeLa cell culture [227]. 

Androderm Testosterone Testosterone deficiency Watson Pharma... 

Estrogen or testosterone deficiency Cushing s syndrome Hyperthyroidism Hyperparathyroidism Immobilization or weightlessness Hematological malignancies (multiple myeloma)... 

Testosterone deficiency during the third trimester impairs phallus growth, a condition called... 

After Completion of Puberty Regression of the pubertal effects of testosterone depends on both the degree and the duration of testosterone deficiency. When the deficiency is severe, libido and energy decrease within a week or two, but other testosterone-dependent characteristics decline more slowly. A clinically detectable decrease in muscle mass does not occur for several years. A pronounced decrease in hematocrit and hemoglobin will occur within several months. A decrease in bone mineral density probably is detectable within 2 years by dual-energy x-ray absorptiometry, but an increase in fracture incidence would not be likely to occur for many years. A loss of sexual hair takes many years. 

MALE HYPOGONADISM The best-established indication for androgen administration is to treat male hypogonadism (testosterone deficiency in men). Any of the transdermal testosterone preparations or testosterone esters described above can be used with good efficacy. 

Arver S, Dobs AS, Meikle AW, et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996 155 1604-1608. 

Cavender RK, Fairall M. Subcutaneous testosterone pellet implant (Testopel ) therapy for men with testosterone deficiency syndrome a single-site retrospective safety anal) is. J Sex Med 2009 6 3177-92. 

Hong, B.S., and Ahn,T.Y. (2007) Recent trends in the treatment of testosterone deficiency syndrome. International Journal of Urology, 14,981-985. 

---